Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides.
Imiquimod is a topical immune response modifier that binds to Toll-like receptors 7 and 8 and induces alpha-interferon. We locally applied imiquimod 5% cream (Aldara) daily for 2 weeks on a PUVA- and retinoid-resistant plaque on the face of a patient with mycosis fungoides. The diagnosis was based on clinical appearance, histology and molecular studies. Most of the disease manifestations showed a clear remission during PUVA therapy combined with low-dose retinoids. However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months.
Dummer
Reinhard
R
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. reinhard.dummer@der.usz.ch
Urosevic
Mirjana
M
Kempf
Werner
W
Kazakov
Dmitry
D
Burg
Günter
G
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000287:Administration, Topical; D000368:Aged; D000634:Aminoquinolines / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D000077271:Imiquimod; D008297:Male; D009182:Mycosis Fungoides / Q000175:diagnosis / Q000188:drug therapy*; D011701:PUVA Therapy; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000077271:Imiquimod